Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
cardiovascular disease
Pharma
Unapproved in US for decades, levosimendan stumbles in ph. 3
Despite the flop, Tenax has zeroed in on a prespecified subgroup of patients with greater disease burden and plans to request a meeting with the FDA.
Angus Liu
Aug 10, 2026 4:40pm
Merck bats for heart disease awareness
Apr 30, 2026 9:30am
Charles River backs AHA to bridge cardiovascular health divide
Apr 10, 2026 10:24am
As questions swirl, Alnylam eyes ATTR market leadership by 2030
Mar 26, 2026 2:08pm
Bayer keeps diners in the dark to shed light on heart health
Feb 13, 2026 10:55am
NIH stops Xarelto arm of stroke trial due to safety, efficacy
Feb 10, 2026 4:04pm
